首页> 外文期刊>Antiviral Research >Inhibition of Henipavirus infection by RNA interference.
【24h】

Inhibition of Henipavirus infection by RNA interference.

机译:RNA干扰抑制肝炎病毒感染。

获取原文
获取原文并翻译 | 示例
       

摘要

Nipah virus (NiV) and Hendra virus (HeV) are recently emerged zoonotic paramyxoviruses exclusively grouped within a new genus, Henipavirus. These viruses cause fatal disease in a wide range of species, including humans. Both NiV and HeV have continued to re-emerge sporadically in Bangladesh and Australia, respectively. There are currently no therapeutics or vaccines available to treat Henipavirus infection and both are classified as BSL4 pathogens. RNA interference (RNAi) is a process by which double-stranded RNA directs sequence-specific degradation of messenger RNA in animal and plant cells. Small interfering RNAs (siRNAs) mediate RNAi by inhibiting gene expression of homologous mRNA and our preliminary studies suggest RNAi may be a useful approach to developing novel therapies for these highly lethal pathogens. Eight NiV siRNA molecules (four L and four N gene specific), two HeV N gene specific, and two non-specific control siRNA molecules were designed and tested for their ability to inhibit a henipavirus minigenome replication system (which does not require the use of live virus) in addition to live virus infections in vitro. In the minigenome assay three out of the four siRNAs that targeted the L gene of NiV effectively inhibited replication. In contrast, only NiV N gene siRNAs were effective in reducing live NiV replication, suggesting inhibition of early, abundantly expressed gene transcripts may be more effective than later, less abundant transcripts. Additionally, some of the siRNAs effective against NiV infection were only partially effective inhibitors of HeV infection. An inverse correlation between the number of nucleotide mismatches and the efficacy of siRNA inhibition was observed. The demonstration that RNAi effectively inhibits henipavirus replication in vitro, is a novel approach and may provide an effective therapy for these highly lethal, zoonotic pathogens.
机译:Nipah病毒(NiV)和Hendra病毒(HeV)是最近出现的人畜共患副粘病毒,仅在一个新属Henipavirus中分组。这些病毒在包括人类在内的多种物种中引起致命的疾病。 NiV和HeV分别继续在孟加拉国和澳大利亚重新出现。当前尚无可用于治疗肝炎病毒感染的疗法或疫苗,两者均被归类为BSL4病原体。 RNA干扰(RNAi)是双链RNA指导动植物细胞中信使RNA序列特异性降解的过程。小型干扰RNA(siRNA)通过抑制同源mRNA的基因表达来介导RNAi,我们的初步研究表明RNAi可能是开发针对这些高致死性病原体的新疗法的有用方法。设计并测试了八个NiV siRNA分子(四个L和四个N基因特异性),两个HeV N基因特异性和两个非特异性对照siRNA分子抑制肝炎病毒微型基因组复制系统的能力(不需要使用活病毒)以及体外活病毒感染。在微型基因组测定中,靶向NiV L基因的四个siRNA中有三个有效抑制了复制。相比之下,只有NiV N基因siRNA可以有效减少NiV的实时复制,这表明抑制早期的,大量表达的基因转录本可能比后期的,较少的转录本更为有效。此外,一些对NiV感染有效的siRNA只是HeV感染的部分有效抑制剂。观察到核苷酸错配的数量与siRNA抑制的功效呈负相关。 RNAi有效抑制体外肝炎病毒复制的证明是一种新颖的方法,可以为这些高度致死的人畜共患病病原体提供有效的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号